A longevity clinical trial listing tells you that a study was registered. It does not tell you that an intervention works, is approved care, or is right for you. One 2026 NMN study in adults age 65 and older raised NAD-related blood measures but did not improve its hearing or physical-performance outcomes over 24 weeks; that is why the exact outcome matters. NMN trial
A clear tracker helps you separate an interesting headline from a result you can use. A University of Michigan poll found that 78% of adults ages 50 to 80 took at least one dietary supplement in a typical week. That makes it useful to bring pills and supplements into the same safety conversation as falls, confusion, and safety at home.
Build one readable row for each longevity study
Keep one row for each trial or published study. Do not combine several studies just because they involve the same supplement, drug, device, or idea.
| Field | What to record |
|---|---|
| Stable identifier | The registry number or publication identifier. |
| Intervention | The exact substance, procedure, or device. |
| Sponsor and location | Who runs it and where participation takes place. |
| Population | Who was studied, including age range and health criteria. |
| Stage and comparison | The phase, if listed, and what the intervention was compared with. |
| Outcome | What the study actually measured, such as hearing, mobility, a blood marker, or daily function. |
| Status and last checked | The registry status and the date you checked that exact record. |
| Exact registry link | The direct record, so you can return to it later. |
For a practical walkthrough of finding ongoing and completed records, see ClinicalTrials.gov guide. If a headline makes you wonder whether a supplement belongs in your daily routine, our daily longevity practices guide offers a non-purchase path to consider too.
Does recruiting mean the treatment is available?
No. “Recruiting” means a study is seeking participants. “Active, not recruiting” means the study is underway but is not adding participants. “Completed” means study activity ended. “Terminated” means it stopped early. “Results published” is different again: it means you can read findings tied to a completed study.
Check the current registry record before you describe access or contact a study team. Record its status and the date you checked it. Registration makes a protocol easier to find; it is not the same as published results or approved care.
Research teams may study a single intervention in different groups and at different stages. The intervention, route, comparison, outcome, and follow-up length all belong in your row. That is especially important when an ad groups different pills or supplements under one “anti-aging” label.
What can an early longevity study tell you?
Early studies often answer narrow questions, such as whether researchers can deliver an intervention and what they observe over a short period. A phase label and an interim announcement do not answer whether an intervention improves independence, prevents falls, clears confusion, or extends life.
The PEARL randomized trial studied weekly compounded rapamycin or placebo for 48 weeks in generally healthy adults ages 50 to 85. Its primary outcome was visceral fat, and that primary outcome was not improved. The study reported selected secondary findings, but those do not establish a general human longevity benefit. PEARL trial results
Use the same rule for a biological-age score or a blood marker: write down what changed, then write down what was actually measured in daily life. A change in one marker is not the same as extra years of life.
What new findings belong in your tracker?
Put peer-reviewed articles, conference abstracts, and sponsor announcements in separate rows or clearly labeled columns. They answer different questions.
- Peer-reviewed article: The September 2026 NMN randomized, double-blind, placebo-controlled trial included healthy adults age 65 and older for 24 weeks. It found higher NAD-related measures, while its primary hearing outcome and physical-performance measures did not improve.
- Published trial report: The PEARL paper reports a completed randomized trial and identifies its primary outcome, comparison, duration, and limits.
- Research program or announcement: Keep it labeled as a program or announcement until a study record and published findings give you the intervention, population, comparison, and outcome.
If you are sorting out NAD-related claims, start with the resveratrol aging profile for background, then return to the exact NMN trial rather than assuming related ingredients have the same result. For broader day-to-day goals, breath and balance practices can help you focus on strength, balance, and safety at home.
What should you ask before considering a study?
Bring this list to a call with the listed research team. Do not enroll based on a headline or sales video.
- What exact intervention is being studied, and what is the main outcome?
- Who is eligible, and what health history, medicines, pills, or supplements need review?
- What does the comparison group receive?
- What visits, travel, tests, and time commitments are involved?
- What costs, reimbursements, and follow-up are described in the consent materials?
- What risks and possible benefits are listed for this exact study?
- Who is the research contact, and what is the registry identifier?
If you have new confusion, a fall, or a sudden change in how you manage medicines, contact a health care provider promptly rather than waiting for a research study.
Printable tool: Emerging therapies evidence and status ledger
Track the exact intervention behind a headline. “New,” “available,” and “studied” mean different things. None alone tells you whether an option fits your needs.
- Write the substance, procedure, or device and the goal being claimed. Record whether the evidence is laboratory, animal, exploratory human research, or a larger controlled trial. Include study dates and the population.
- Check regulatory status for the exact product, route, and intended use. Separate an approved or cleared use from a different advertised longevity use. A trial listing or registration is not the same as authorization to market a treatment.
- Record what improved, what did not, what was not measured, and how long follow-up lasted. Include reported harms and whether independent groups replicated the result. Do not replace these details with a single confidence score.
- Add practical burdens, total known cost, and a question for a qualified professional. Revisit the record when a new trial, regulatory decision, or product version changes a meaningful part of the answer.
Intervention and claimed goal: ____________________
Research/status checked on: ____________________
Important unanswered question: ____________________
Next evidence milestone: ____________________
| Source/date | Research or regulatory stage | Population/use | Measured result or status | Limits and next question |
|---|---|---|---|---|
Illustration: One record describes an ongoing trial; another describes an authorized device for a specific eye condition. The ledger keeps those categories separate and gives neither a universal “approved for anti-aging” label.
This is an information record, not a treatment ranking, enrollment recommendation, or permission to use an investigational product.
Disclosure: This page contains no research-chemical shopping links and does not enroll readers in studies.
By the Senior Safety Desk Editorial Team